Categories: DNANews

OccuPro Launches POET 4.0: Revolutionary Upgrade to Post Offer Employment Testing Software

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

KENOSHA, WI / ACCESSWIRE / October 1, 2024 / OccuPro, a leader in employment testing software, proudly announces the release of POET 4.0, the latest and most advanced version of its Post Offer Employment Testing (POET) software. Designed to streamline the testing process, enhance efficiency, and improve the user experience, POET 4.0 is set to revolutionize how clinics and employers handle employment testing and job analysis.

Job Demands Match
Picture of screen with a job demands match report.

Jim Mecham, MSIE, OTR/L, CPE, President, Chief Operating Officer and co-founder of OccuPro, stated, “POET 4.0 represents a leap forward in post-offer employment testing. We’ve listened to feedback from clinics and employers and have built a system that not only streamlines their work but provides the fastest, most accurate solution on the market. The improved technology infrastructure and added features make POET 4.0 the best choice for those needing legally defensible employment screens. We’re excited to offer this new solution to our customers, and we believe it will profoundly impact their ability to deliver high-quality, efficient testing.”

POET 4.0 Key Upgrades Include:

  • Improved Employer Login Dashboard: Employers can now enjoy an enhanced view of all data with upgraded scheduling capabilities through a more intuitive and streamlined dashboard.

  • Streamlined POET Creation: Users can now create customized Post Offer Tests faster with a more intuitive process to build tailored assessments.

  • Locked Customizations: POET 4.0 ensures consistency by allowing users to set and lock customizations within the POET template, preventing unintentional modifications and guaranteeing standardized testing.

  • Simplified Calendar Feature: The calendar system has been revamped, allowing users to view appointments across all schedulers.

  • Job Description-Driven POET Creation: With POET 4.0, users can now create a simplified Post Offer Test based on an employer-provided job description without needing to fill out additional fields.

  • Comprehensive Job Analysis Templates: For more complex analyses, POET 4.0 allows the inclusion of unlimited essential function tests within job analysis templates, making the creation of detailed and thorough assessments easier than ever before.

  • Latest Web-Based Technology: POET 4.0 has undergone a significant infrastructure upgrade. This shift ensures a faster, more secure, and more reliable experience, offering lightning-fast load times with the industry’s fastest Post Offer testing system.

  • Enhanced Snippets & Quick Notes: With improved snippets and a new custom quick notes feature, users can access pre-loaded documentation faster and complete Post Offer Tests quicker.

  • Voice-to-Text Documentation: The new voice-to-text feature allows users to dictate results directly into the system, improving speed and accuracy in documenting Post Offer Tests.

POET 4.0 is now available for current and new customers. For more information or to schedule a demo, visit OccuPro’s website.

Contact Information

Briena Jacob
Director of Marketing
bjacob@occupro.net
866.470.4440

SOURCE: OccuPro

View the original press release on newswire.com.

Staff

Recent Posts

TMCI Deadline: Rosen Law Firm Urges Treace Medical Concepts, Inc. (NASDAQ: TMCI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a…

15 hours ago

Introducing Tempus One in the EHR with Integrated Guidelines

The AI-enabled clinical assistant is available to query patient data across the EHR as well…

18 hours ago

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC)…

18 hours ago

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep,…

18 hours ago